Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Demetri, George
Item TypeName
Academic Article Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
Academic Article KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
Academic Article Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.
Academic Article Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Academic Article Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.
Academic Article Small molecule tyrosine kinase inhibitor and depression.
Academic Article Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase inhibitors.
Academic Article Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.
Academic Article Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors.
Academic Article Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
Academic Article The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
Academic Article Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.
Academic Article Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
Academic Article Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).
Academic Article Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin.
Academic Article Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Academic Article Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
Academic Article Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in GIST.
Academic Article Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec.
Academic Article A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
Academic Article Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
Academic Article Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
Academic Article Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours.
Academic Article Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
Academic Article Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
Academic Article First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies.
Concept Protein Kinase Inhibitors
Academic Article Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors.
Academic Article Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
Academic Article A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.
Academic Article KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.
Academic Article Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.
Academic Article Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.
Academic Article Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.
Academic Article Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT).
Academic Article Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
Academic Article Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
Academic Article Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Academic Article Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
Academic Article Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.
Academic Article Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
Academic Article Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence.
Search Criteria
  • Protein Kinase Inhibitors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.